Skip to main content

KYMR Kymera Therapeutics, Inc.

Healthcare

107.39

Close 10/2

P/B
5.9
Loading candles…

Is Kymera Therapeutics, Inc. a buy? Fundamentals and valuation first

As of 2026-10-02

Growth: Good, Momentum: Good, Risk / liquidity: Good; Valuation: Pricey, Quality: Weak.

Valuation Pricey TTM P/E is Cheap, but Price / book is Expensive.
TTM P/E -33.04 8th percentile Cheap
Price / book 5.92 87th percentile Expensive
Free-cash-flow yield (%) -2.66 34th percentile Average
Quality Weak ROE, TTM is Average; Operating margin, TTM is Lagging.
ROE, TTM (%) -19.85 25th percentile Average
Operating margin, TTM (%) -333.54 8th percentile Lagging
FCF margin, TTM (%) -226.65 9th percentile Lagging
Growth Good Revenue growth, TTM YoY is Top; Diluted EPS growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 134.82 93th percentile Top
Diluted EPS growth, TTM YoY (%) -6.34 53th percentile Good
Momentum Good 240-day return is Top, but 60-day return is Average.
60-day return (%) -9.76 37th percentile Average
240-day return (%) 79.49 92th percentile Top
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Fair.
20-day dollar volume 89,686,318 86th percentile Top
60-day annualized volatility (%) 39.32 44th percentile Fair

Kymera Therapeutics, Inc. (KYMR) today

1 quant signals active · As of 2026-10-02

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Kymera Therapeutics, Inc. (KYMR) peers and tracking

Watchlist

This page refreshes daily after the close. Add Kymera Therapeutics, Inc. to your watchlist to track signal changes on your next visit.

Kymera Therapeutics, Inc. (KYMR) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 134.81693542976%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

5 historical occurrences (since 2024-02-22)

Over 5 occurrences, 20-day forward avg gained 3.76%, beat the market by 0.15 pts; win rate 80%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 98,443 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.22%, a 57.8% positive-return rate, and +2.86 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

9 times historically; 60-day forward avg +7.05%, win rate 50%, beating the market by +3.22 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

15 times historically; 60-day forward avg +10.31%, win rate 64.3%, beating the market by +6.67 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

6 times historically; 60-day forward avg +17.62%, win rate 80%, beating the market by +10.32 pts on average.

Continue researching Kymera Therapeutics, Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.